Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
AssigneesInstitut National De La Sante Et De La Recherche Medicale (Inserm), Université Paris Cité, Centre National de la Recherche Scientifique (CNRS), Assistance Publique-Hopitaux de Paris, Imagine Ltd.
InventorsLaurence LEGEAI-MALLET, Arnold MUNNICH, Patricia BUSCA, Florent BARBAULT
Life of this patent
Estimating the term…
Abstract
The present invention relates to the treatment or prevention of skeletal disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3.
Claims2
A method comprising administering a therapeutically effective amount of the compound having the structure:
- to a subject, thereby treating achondroplasia in the subject.
A method comprising administering a therapeutically effective amount of the compound having the structure:
- to a subject, thereby treating hypochondroplasia in the subject.
Dependencies are inferred from the claim text.